Colon Cancer Liquid Biopsy Investigation of Methylation-based Biomarkers Evaluation Using Delta-HLD (CLIMBED)

Recruiting now

Conditions studied: Colorectal Cancer (CRC)

In brief

CLIMBED (Colon cancer Liquid biopsy Investigation of Methylation-based Biomarkers Evaluation using Delta-HLD) is a non-randomized, observational, cross-sectional clinical validation study designed to assess the performance of Delta-HLD, Epiliquid's proprietary liquid biopsy technology, for colorectal cancer (CRC) detection. The study will evaluate the test performance in an average-risk population for CRC undergoing screening colonoscopy, which will serve as the gold standard reference.

Key facts

Study ID

NCT07168876

Run by

Epiliquid Holding, Inc

People needed

3200

Starts

2024-04-04

Expected to finish

2028-12-01

Last updated by the study team

2025-09-11

Who can join

Age: 45 and older, up to 75. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Men and women aged 45-75 years
• Indication of colorectal cancer screening colonoscopy by treating physician

You may not qualify if…

• First-degree family history of CRC
• Inflammatory bowel disease (ulcerative colitis, Crohn's disease)
• Other malignancies within 5 years
• Known hereditary CRC syndromes (Lynch, FAP)
• Major trauma, surgery, transfusion in past 30 days
• Current participation in an interventional clinical trial

Where it is running

• Epiliquid — Mendoza, Mendoza Province, Argentina (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.